CureVac signs new deal with Sanofi; firms win $33.1M US DARPA vaccine contract
This article was originally published in Scrip
Executive Summary
CureVac inked a new deal potentially worth more €150.5 million involving its RNActive technology platform with Sanofi Pasteur to develop vaccines against several infectious diseases, with the parties also winning a four-year $33.1 million research contract from the US Defense Advanced Research Projects Agency (DARPA) to evaluate several vaccine candidates.